Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic ...

The global Radioligand Therapy (RLT) market is poised to reach US$13 billion by 2030, expanding at a ~5% CAGR over the ...

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics, Therapeutics), Application ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the ...

Financial giant UBS has declared that enough is enough with lagging healthcare valuations – and now believes it will be the ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

TOKYO, Japan I June 30, 2025 I Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, ...

While the Australian market is relatively well-positioned, it is vulnerable to broader market shocks, says SG Hiscock & ...

Twenty years later, the Maimonides Cancer Center spans 18 oncology specialties, from breast and lung cancer to prostate and ...

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.